In the first half of the year, net profit was 1.3 billion, and the "Chinese Medicine Mao" Pianzi paid the papers. Why not buy the market?

Since the "holding group" funds disintegrated, all kinds of "Mao" no longer eats incense.

On July 18, the "Chinese Medicine Mao" Pianzi released the performance of the first half of 2022. The Express showed that in the first half of 2022, Pianzai achieved revenue of 4.423 billion yuan, an increase of 14.91%year -on -year; net profit was 1.314 billion yuan, a year -on -year increase of 17.83% ; Deducting non -net profit was 1.316 billion yuan, an increase of 18.09%year -on -year.

It stands to reason that the continued growth of performance is a good thing, but the market has not bought it. On July 19, Pianzi opened low and walked down, and the session fell nearly 5%for a time. As of the day's close, it still fell 2.88%. If the decline in the year, then the decline of Pianzai is close to 30%.

So, why is the market neglecting the performance of Pianzai's growth? Will Pianzi continue to maintain a double -digit growth trend in the future? Is the current Pianzi be underestimated by the market?

First of all, although since 2010, Pianzai's performance has maintained a relatively stable growth rate, after a wave of stir -fry last year, the space of Pianzi is a bit overdraft. At present, up to 71 times the dynamic price -earnings ratio and 18.27 times that the net ratio is relatively high than its peers.

In addition, since the second half of last year, the entire pharmaceutical industry has not performed well. Therefore, after Pianzi 癀 released the performance fast report, the market response was normal.

Secondly, starting from the second half of last year, the price of 590 yuan was fired all the way to up to 1600 yuan. Not only that, but Pianzi also began to restrict purchase, which increased the scarcity of Pianzai, which eventually led to the market heating. So whether such a high price can stabilize for a long time is essential for Shiba.

In the semi -annual report of Pianzi, for the growth of performance, Pianzi said that it was the increase in market planning and expanding sales channels, and the sales revenue of the company and the holding subsidiary Xiamen Pianzi Hongren Pharmaceutical Co., Ltd. (merger) increased. In other words, its performance growth still depends on Shiba Tsai series products.

Therefore, as long as the valuation is reasonable, the market acceptance is still relatively high. In addition, the pads outside the pharmaceutical sector also cut into the beauty field.

Earlier this year, Pianzi disclosed a capacity expansion project of up to 4.48 billion yuan. Pianzi intends to establish a new industrial park in Zhangzhou, Fujian, including large health manufacturing parks and healthy makeup parks. It can be said that in the future, cosmetics are also one of the main directions of Pianzai.

In 2021, Pianzi Tsai announced the launch of the listing of the spin -off cosmetics sector, and also spent 150 million yuan to establish Fujian Pianzi Cosmetics Trading Co., Ltd., which was 100%controlled by Fujian Shizi Cosmetics Co., Ltd. In March of this year, Pianzi also established Xiamen Shibai Hongren Lake Afrot Health Management Co., Ltd., which includes living beauty services; in addition, on March 27, Pianzi Subordinate Company Pianzi Cosmetics Co., Ltd. also issued a bidding announcement, the highest bidding project bidding project, the highest bidding amount The limit price is 711 million yuan. It can be seen that the future strategy of Pianzai is relatively clear.

In the end, although the stock price of Pianzai has fallen this year and the decline of nearly 30%, its current market value is not low, still as high as 186.6 billion yuan.

In summary, I think that although the performance of Pianzai has continued to grow and stable, the market valuation takes time to digest. For the "Chinese Medicine Mao" Pianzi, as long as the performance has not exceeded the market's prediction, its stock price will still follow its own trend according to its own trend Continue digestion valuation.

- END -